- Home
- WERN vs VRDN Comparison
WERN vs VRDN Comparison
Compare WERN & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WERN
- VRDN
- Stock Information
- Founded
- WERN 1956
- VRDN 2006
- Country
- WERN United States
- VRDN United States
- Employees
- WERN N/A
- VRDN N/A
- Industry
- WERN Trucking Freight/Courier Services
- VRDN Medical Specialities
- Sector
- WERN Industrials
- VRDN Health Care
- Exchange
- WERN Nasdaq
- VRDN Nasdaq
- Market Cap
- WERN 1.7B
- VRDN 1.5B
- IPO Year
- WERN N/A
- VRDN N/A
- Fundamental
- Price
- WERN $28.01
- VRDN $18.87
- Analyst Decision
- WERN Hold
- VRDN Strong Buy
- Analyst Count
- WERN 13
- VRDN 11
- Target Price
- WERN $31.08
- VRDN $38.80
- AVG Volume (30 Days)
- WERN 618.2K
- VRDN 877.5K
- Earning Date
- WERN 10-28-2025
- VRDN 11-11-2025
- Dividend Yield
- WERN 2.00%
- VRDN N/A
- EPS Growth
- WERN N/A
- VRDN N/A
- EPS
- WERN 0.85
- VRDN N/A
- Revenue
- WERN $2,965,642,000.00
- VRDN $305,000.00
- Revenue This Year
- WERN $1.11
- VRDN N/A
- Revenue Next Year
- WERN $5.68
- VRDN $35,092.81
- P/E Ratio
- WERN $32.98
- VRDN N/A
- Revenue Growth
- WERN N/A
- VRDN 5.90
- 52 Week Low
- WERN $23.02
- VRDN $9.90
- 52 Week High
- WERN $42.48
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- WERN 47.40
- VRDN 52.46
- Support Level
- WERN $27.27
- VRDN $18.12
- Resistance Level
- WERN $28.78
- VRDN $20.51
- Average True Range (ATR)
- WERN 0.73
- VRDN 0.94
- MACD
- WERN -0.08
- VRDN -0.01
- Stochastic Oscillator
- WERN 30.20
- VRDN 34.66
About WERN Werner Enterprises Inc.
Werner Enterprises Inc is a transportation and logistics company. The company has two reportable segments - Truckload Transportation Services and Werner Logistics. It derives majority of its revenue from full-truckload transportation services and geographically from United States.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).